In head-to-head studies, a next-generation EGFR inhibitor and an ALK inhibitor beat their older counterparts in staving of cancer progression.
Quest Diagnostics will offer the Target Selector lung cancer mutation detection test in that country through a reference agreement with Biocept.
Non-small cell lung cancer patients with EGFR mutations now have three treatment choices, and AstraZeneca is working on newer personalized treatment options.
The raise is an extension of a $27 million Series B round in early 2014 to prepare for the launch of several liquid biopsy cancer tests this year.
Data presented at the meeting helped better define the potential benefits and risks of broad panel-based tests for hereditary cancer genes.
The results also suggest the cfDNA assay has high sensitivity and 100 percent specificity, comparable to other technologies being developed for liquid biopsy testing.
Clovis hopes Sysmex's BEAMing test will work better than FFPE tests to identify candidates for treatment with rociletinib, its investigational EGFR inhibitor.
NEW YORK (GenomeWeb) — Researchers from several European institutions working with AstraZeneca have published a study demonstrating that measuring EGFR mutations from circulating tumor DNA compares favorably to tissue-based EGFR mutation status.
Originally published May 7.
Boehringer Ingelheim has launched a campaign to educate healthcare providers about biomarker testing to personalize treatment for non-small cell lung cancer patients.
The US Food and Drug Administration has new guidelines that enable some gene and cell therapies to undergo expedited review, according to the New York Times.
Using gene drives to control invasive species might be too risky, an initial advocate of the approach says.
Researchers have grown tumors in 3D cell cultures to better understand cancer, the Economist reports.
In Science this week: intellectual property experts argue patent battles such as the one over CRISPR are wasteful, and more.